Evidence map›Paper›PMID 41146875›Full record

ArticleMolecular therapy. Methods & clinical development2025

Efficient kidney gene transfer and proximal tubule transduction using self-complementary AAV.cc47 vectors.

Jennifer L Peek, Alan Rosales, Julie Qi, Lena Feleke, Anna Menshikh, Richard C Welch, Lauren E Woodard, Aravind Asokan, Matthew H Wilson

Erratum issuedAbstract read
In one paragraph

Article in Molecular therapy. Methods & clinical development, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Jennifer L PeekMedical Scientist Training Program, Vanderbilt University, Nashville, TN, USA.
Alan RosalesDepartment of Biomedical Engineering, Duke University, Durham, NC, USA.
Julie QiDepartment of Medicine, Division of Nephrology and Hypertension, Vanderbilt University Medical Center, Nashville, TN, USA.
Lena FelekeDepartment of Medicine, Division of Nephrology and Hypertension, Vanderbilt University Medical Center, Nashville, TN, USA.
Anna MenshikhDepartment of Medicine, Division of Nephrology and Hypertension, Vanderbilt University Medical Center, Nashville, TN, USA.
Richard C WelchDepartment of Medicine, Division of Nephrology and Hypertension, Vanderbilt University Medical Center, Nashville, TN, USA.
Lauren E WoodardDepartment of Medicine, Division of Nephrology and Hypertension, Vanderbilt University Medical Center, Nashville, TN, USA.
Aravind AsokanDepartment of Biomedical Engineering, Duke University, Durham, NC, USA.
Matthew H WilsonDepartment of Cell and Developmental Biology, Vanderbilt University, Nashville, TN, USA.

Funding

MEDICAL SCIENTIST TRAINING PROGRAMT32GM007347 · NIGMS · VANDERBILT UNIVERSITY · PI WILLIAMS, CHRISTOPHER S. · 1985 to 2023
$26.3M
Determinants of AAV TropismR01HL089221 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Aravind Asokan · 2009 to 2026
$8.1M
Vanderbilt O'Brien Kidney Center - Core D - Clinical and Translational CoreP30DK114809 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI DE CAESTECKER, MARK P. · 2017 to 2021
$5.9M
Medical Scientist Training ProgramT32GM152284 · NIGMS · VANDERBILT UNIVERSITY · PI Christopher S. Williams · 2024 to 2026
$4.8M
Novel cell therapy for sustained therapeutic protein delivery in vivoR01DK093660 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI WILSON, MATTHEW H · 2012 to 2022
$3.4M
Genetic engineering of kidney allografts by ex vivo perfusion delivery of adeno-associated viral vectorsU01AI170064 · NIAID · DUKE UNIVERSITY · PI Aravind Asokan, Andrew Serghios Barbas · 2022 to 2026
$2.4M
Evolving High Potency AAV Vectors for Neuromuscular Genome EditingUG3AR075336 · NIAMS · DUKE UNIVERSITY · PI ASOKAN, ARAVIND · 2018 to 2020
$2.1M
Evolving High Potency AAV Vectors for Neuromuscular Genome EditingUH3AR075336 · NIAMS · DUKE UNIVERSITY · PI ASOKAN, ARAVIND · 2021 to 2022
$2.0M
Next generation transposon vectors for genome engineeringR01EB033676 · NIBIB · VANDERBILT UNIVERSITY MEDICAL CENTER · PI WILSON, MATTHEW H · 2022 to 2025
$2.0M
Kidney targeted AAV for gene therapyR01DK143088 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Aravind Asokan, MATTHEW H WILSON · 2025 to 2026
$1.7M
BLRD VA I01 BX002190BLRD VA I01 BX004258BLRD VA I01 BX004845BLRD VA I21 BX006554BLRD VA IK2 BX002797NHLBI NIH HHS R01 HL089221NIAID NIH HHS U01 AI170064NIAMS NIH HHS UG3 AR075336NIAMS NIH HHS UH3 AR075336NIBIB NIH HHS R01 EB033676NIDDK NIH HHS P30 DK114809NIDDK NIH HHS R01 DK093660NIDDK NIH HHS R01 DK143088NIGMS NIH HHS T32 GM007347NIGMS NIH HHS T32 GM152284
6 · The paper itself

Abstract

Gene delivery to critical cell types within the kidney can enable preclinical evaluation of gene therapies for kidney disease. The novel adeno-associated virus AAV.cc47 was discovered after sequential evolution in mice, pigs, and macaques and improved transduction in multiple tissues but without in-depth exploration of the kidney. We observed robust kidney transduction by AAV.cc47 vectors in mice

Indexed as

AAVgene therapykidneyproximal tubule

Identifiers

PMID41146875
PMCPMC12554119

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.